Drug Trial Radar · NCT06627179
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
81
Planned (sponsor's estimate)
Start
Dec 11, 2024
Primary completion
Jul 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Laboratoires TheaIndustry
- Sponsor type
- Industry
- Collaborators
- Sepul Bio
- First posted
- Oct 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.
Conditions
- Retinitis Pigmentosa (RP)
- Usher Syndrome Type 2
- Deaf Blind
- Retinal Disease
- Eye Diseases, Hereditary
- Eye Disorders Congenital
- Vision Disorders
Interventions
Intravitreal Injection of UltevursenDrug
Up to 4 doses over a 24-month period
No intervention, will not receive any active study interventionOther
Sham-procedure (no experimental drug administered)
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate efficacy after 24 months of treatmentTime frame: 24 Months
Locations
26 sites in 10 countries. Site status is shown where the registry gives one.
The University of California, San Francisco
San Francisco, California
Bascom Palmer Eye Institute/University of Miami
Miami, Florida
Emory University
Atlanta, Georgia
Massachusetts Eye and Ear
Boston, Massachusetts
University of Michigan- Kellogg Eye Center
Ann Arbor, Michigan
Casey Eye Institute, Oregon Health & Science University
Portland, Oregon
University of Pennsylvania, Scheie Eye Institute
Philadelphia, Pennsylvania
Retina Foundation of the Southwest
Dallas, Texas
Baylor College of Medicine
Houston, Texas
University of Wisconsin- Madison
Madison, Wisconsin
Ghent University Hospital
Ghent, Belgium
INRET Clínica/ Santa Casa de Misericórdia de Belo Horizonte
Belo Horizonte, Brazil
Federal University of São Paulo - Hospital São Paulo (UNIFESP-HSP)
São Paulo, Brazil
Hospital for Sick Children
Toronto, Ontario, Canada
McGill University Health Centre for Innovative Medicine
Montreal, Quebec, Canada
Rigshospitalet and University of Copenhagen
Glostrup Municipality, Denmark
Hôpital Gui de Chauliac - CHRU de Montpellier - Maladies Sensorielles Génétique
Montpellier, France
Centre de maladies rares CHNO des Quinze Vingt
Paris, France
Universitätsklinikum Tübingen
Tübingen, Germany
ASST Santi Paolo e Carlo Hospital, University of Milan
Milan, Italy
Amsterdam University Medical Center - Locatie AMC
Amsterdam, Netherlands
Radboud Universitair Medisch Centrum
Nijmegen, Netherlands
Het Oogziekenhuis Rotterdam
Rotterdam, Netherlands
University of Edinburgh / NHS Lothian
Edinburgh, United Kingdom
Moorfields Eye Hosptial
London, United Kingdom
Oxford Eye Hospital
Headington, Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.